Your browser is no longer supported. Please, upgrade your browser.
SNY Sanofi daily Stock Chart
Index- P/E23.47 EPS (ttm)2.10 Insider Own- Shs Outstand2.63B Perf Week-0.46%
Market Cap129.59B Forward P/E15.12 EPS next Y3.26 Insider Trans- Shs Float2.36B Perf Month-8.01%
Income5.53B PEG2.64 EPS next Q- Inst Own9.70% Short Float0.09% Perf Quarter-0.02%
Sales41.44B P/S3.13 EPS this Y18.70% Inst Trans-1.96% Short Ratio1.27 Perf Half Y5.45%
Book/sh24.17 P/B2.04 EPS next Y2.84% ROA5.10% Target Price57.50 Perf Year-6.91%
Cash/sh1.99 P/C24.73 EPS next 5Y8.90% ROE8.80% 52W Range42.16 - 55.57 Perf YTD11.65%
Dividend1.61 P/FCF- EPS past 5Y-3.90% ROI7.00% 52W High-11.31% Beta1.16
Dividend %3.27% Quick Ratio1.40 Sales past 5Y1.80% Gross Margin68.00% 52W Low16.88% ATR1.17
Employees113496 Current Ratio1.40 Sales Q/Q16.10% Oper. Margin20.60% RSI (14)40.29 Volatility2.61% 1.67%
OptionableYes Debt/Eq0.26 EPS Q/Q69.70% Profit Margin13.10% Rel Volume0.64 Prev Close50.08
ShortableYes LT Debt/Eq0.19 EarningsJul 30 BMO Payout43.20% Avg Volume1.70M Price49.28
Recom1.70 SMA20-5.65% SMA50-4.81% SMA2001.69% Volume1,091,901 Change-1.60%
Apr-22-15Upgrade Citigroup Sell → Neutral
Apr-15-15Initiated Societe Generale Buy
Aug-03-12Downgrade Standpoint Research Buy → Hold
Jan-11-11Downgrade Jefferies Buy → Hold
Nov-16-09Initiated Deutsche Securities Buy
Oct-14-09Upgrade UBS Sell → Neutral
Aug-28-09Upgrade JP Morgan Neutral → Overweight
Jun-29-09Downgrade JP Morgan Overweight → Neutral
May-28-09Upgrade Citigroup Hold → Buy
Apr-30-09Upgrade JP Morgan Neutral → Overweight
Mar-23-09Upgrade Jefferies & Co Underperform → Hold
Mar-17-09Initiated Credit Suisse Outperform
Feb-19-09Upgrade JP Morgan Underweight → Neutral
Jan-26-09Initiated Jefferies & Co Underperform
Nov-07-08Downgrade UBS Neutral → Sell
Sep-23-08Downgrade Credit Suisse Neutral → Underperform
Oct-24-07Initiated Bernstein Mkt Perform
Sep-06-07Initiated UBS Neutral
Jul-18-07Upgrade HSBC Securities Neutral → Overweight
Jun-14-07Reiterated Banc of America Sec Buy $50 → $48
Aug-28-15 10:35AM  Amgen's PCSK9 Inhibitor, Repatha, Approved in the U.S.
08:37AM  Time to Buy Amgen After Newly Approved Drug? at TheStreet
Aug-27-15 06:49PM  Amgen's Repatha OK'd With Similar Label To Praluent at Investor's Business Daily
03:40PM  Oncolytics' Reolysin Phase II Lung Cancer Study Enrolled
02:31PM  Cholesterol drug wars
11:24AM  Germany Helps Eurozone Business Activity Rise in August Market Realist
06:28AM  Cholesterol drug wars: Amgen
Aug-26-15 04:12PM  MannKind And Afrezza: Can The Drug Cure The Company? at Forbes
Aug-25-15 12:04PM  3 Reasons Why Afrezza's Launch Has Been So Disappointing at Motley Fool
Aug-23-15 10:57AM  The 3 Most Disappointing Drug Launches of All Time at Motley Fool
Aug-20-15 05:54PM  Dividend cuts for big oil?
05:42PM  Cholesterol war heats up
11:02AM  This Is a Concern That Amgen Investors Shouldn't Take Lightly at Motley Fool
Aug-19-15 04:12PM  MannKind Backers Still Drinking The Kool-Aid As Stock Slips Below $4 at Forbes
Aug-18-15 11:22AM  Esperion Drug Update Gets Mixed Wall Street Reaction at Investor's Business Daily
10:33AM  Wait, There are Still Cheap Pharma Stocks? at
Aug-17-15 05:25AM  Research and Markets: Investigation Report on China's Polyene Phosphatidyl Choline Market 2010-2019 Business Wire
Aug-14-15 07:08PM  John Buckingham Buys 10 New Stakes in Second Quarter
03:18PM  Inflation Rate in France Fell to 0.20% in July: EWQ Fell 1.14%
11:30AM  VCEL: Solid Q2 Financial Results. Expect Continued Revenue Growth in 2H 2015
Aug-13-15 11:42AM  Payers Set To Play Hardball On PCSK9 Pricing: RBC at Investor's Business Daily
10:04AM  The Chemical Works of Gedeon Richter Plc Earnings Q2*, 2015
09:20AM  Immune Design's Q2 Loss Narrows Y/Y, Focus on Pipeline
Aug-12-15 12:59PM  Make Room for Exelixis in Your Portfolio at Investopedia
10:14AM  Takeda Pharmaceutical Co., Ltd. Earnings Q2*, 2015
10:12AM  Dr. Reddys Laboratories Ltd. Earnings Q2*, 2015
09:30AM  Regeneron Pharmaceuticals, Oshkosh, Amgen and Caterpillar highlighted as Zacks Bull and Bear of the Day
Aug-11-15 04:18PM  Industrial Production in France Dipped in June, yet EWQ up 1.11%
12:20PM  MannKind (MNKD) Reports Narrower-than-Expected Q2 Loss - Analyst Blog
08:13AM  Once Disparaged, 'Me-Too' Drugs Crucial For Lower Costs Of Cholesterol, Hepatitis C And Cancer Drugs at Forbes
Aug-10-15 04:06PM  Relypsa Enters Two-Year Detailing Agreement With Sanofi in the United States GlobeNewswire
03:23PM  MannKind: Going Nowhere Fast? at
03:15PM  Sanofi Inks Deals, Diabetes and Immuno-Oncology in Focus
08:00AM  SNY's new cancer fighting team
Aug-07-15 06:10AM  Biotech Stock Mailbag: Controversial Stocks Revisited at TheStreet
Aug-05-15 12:16PM  Why MannKind Got the Unkind Treatment From Investors in July at Motley Fool
08:03AM  Will Regeneron's New Drug Break The Bank? at Motley Fool
Aug-04-15 01:05PM  Regeneron Pops On Upbeat Q2 at
07:16AM  Regeneron Pharmaceuticals Profit Doubles at The Wall Street Journal
04:00AM  Sanofi's Insulin Toujeo® now Available for the Treatment of Adults with Diabetes in the UK PR Newswire
Aug-03-15 11:40AM  Regeneron Still Has Legs: Leerink Targets $630 a Share at
08:48AM  Biogen, Inc. Earnings Analysis: By the Numbers Q2*, 2015
08:00AM  New Analysis Reports Lower Rates of Serious Cardio-Respiratory Events Among Study Participants Administered Higher-Dose Influenza Vaccine PR Newswire
Jul-31-15 12:06PM  Sanofi Tops Q2 Earnings, Revenues Grow Y/Y, Maintains View - Analyst Blog
Jul-30-15 06:10PM  Sanofi (SNY) Earnings Report: Q2 2015 Conference Call Transcript at TheStreet
04:18PM  Amgen beats big on bottom line
03:40PM  Sales of MannKind's inhaled insulin continue slow start at Los Angeles Times
03:00PM  How many multiple sclerosis patients are in the U.S.? No one knows. at
12:44PM  Why MannKind Corp. Stock Briefly Dropped Today at Motley Fool
12:13PM  10 Stocks Making Warren Buffett Richer in 2015 at TheStreet
11:52AM  MannKind slumps after Sanofi details Afrezza sales
11:03AM  MannKind Afrezza Sales Underwhelming Again, Sanofi Reports at TheStreet
07:40AM  Sanofi calls out Genzyme, multiple sclerosis drug, as main drivers of growth again at
07:30AM  A Health Care ETF Making new Highs
07:30AM  Sanofi Delivers Solid Sales and Business EPS Growth in Q2 2015 PR Newswire
06:39AM  Strong dollar helps push Sanofi profit higher in second quarter at Financial Times
04:54AM  Sanofi's diabetes sales slow, Genzyme's jump
03:56AM  Sanofi Buoyed by Biotech and Lower Costs at The Wall Street Journal
02:45AM  Sanofi H1 2015 Results - Interview with CEO Olivier Brandicourt PR Newswire
02:36AM  Sanofi's diabetes division sales slow in Q2, Genzyme jumps
01:35AM  Sanofi Profit Beats Estimates on Multiple Sclerosis Drugs at Bloomberg
01:30AM  Sanofi Profit Beats Estimates as Multiple Sclerosis Drugs Gain at Bloomberg
12:33AM  Sanofi delivers solid sales and business EPS(1) growth in Q2 2015 ACN Newswire
Jul-29-15 03:45PM  Sanofi & Regeneron Enter Immuno-Oncology Collaboration - Analyst Blog
11:27AM  Sanofi-Regeneron: Third Time's the Charm? at
08:00AM  Genzyme Launches Fifth Annual Patient Advocacy Leadership (PAL) Awards Program Business Wire
07:00AM  Sanofi Announces that First LixiLan Phase III Study Met Primary Endpoint PR Newswire
Jul-28-15 08:07PM  5 Hot Drug Stocks Top IBD's Big Cap Leaders Screen at Investor's Business Daily
05:32PM  Pfizer, Merck Beat Q2 Views; Sanofi Makes PD-1 Deal at Investor's Business Daily
03:52PM  Eurozone Business Activity Seems Undeterred by Greek Crisis
01:57PM  Regeneron Shares Rising After Sanofi Collaboration Revealed: Good News For Shareholders?
11:08AM  Regeneron's George Yancopoulos Becomes Pharma's First Billionaire R&D Chief at Forbes
10:23AM  Struggling Sanofi Sends Cancer SOS to Regeneron and Another Vanity Biotech IPO Launches at TheStreet
02:42AM  Sanofi links with Regeneron in $2.2 bln cancer drug push
01:00AM  Sanofi Joins Regeneron in $2.2 Billion Pact for Cancer Therapies at Bloomberg
01:00AM  Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration PR Newswire
Jul-27-15 02:56PM  Regeneron Pharmaceuticals and Sanofi Grab a Blockbuster FDA Approval at Motley Fool
01:55PM  Sanofi paying up to $300M for rare thyroid cancer drug
12:43PM  Why Regeneron's Approval is Bad News For Esperion Therapeutics at
11:53AM  Have Analysts Fully Priced in Praluent to Regeneron?
10:00AM  AZN sells off non-core drugs
02:00AM  Genzyme Strengthens Endocrinology Portfolio with Acquisition of Rare Disease Therapy Caprelsa® (vandetanib) from AstraZeneca Business Wire
Jul-24-15 05:24PM  Regeneron/Sanofi PCSK9 Cholesterol Drug Wins FDA OK at Investor's Business Daily
05:24PM  Regeneron Cholesterol Fighter Wins FDA OK, With Conditions
03:53PM  Sanofi and Regeneron Announce FDA Approval of Praluent® (alirocumab) Injection, the First PCSK9 Inhibitor in the U.S., for the Treatment of High LDL Cholesterol in Adult Patients PR Newswire
03:17PM  Regeneron and Sanofi Announce FDA Approval of Praluent® (alirocumab) Injection, the First PCSK9 Inhibitor in the U.S., for the Treatment of High LDL Cholesterol in Adult Patients PR Newswire
02:43PM  Sanofi Cholesterol Drug Approved in U.S. for Some Patients at Bloomberg
07:15AM  Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia PR Newswire
Jul-23-15 01:04PM  The Future Of MannKind at Insider Monkey
Jul-22-15 04:25PM  Amgen's Repatha Gains EU Nod; First PCSK9 Drug Approved - Analyst Blog
03:59PM  Actelion Misses on Q2 Earnings, Revenues Beat Expectations - Analyst Blog
12:45PM  Abbott Laboratories (ABT) Beats on Q2 Earnings, Keeps View - Analyst Blog
03:37AM  Amgen and Sanofi to battle for cholesterol-busting crown at Financial Times
Jul-20-15 12:30PM  Why Genzyme isn't worried about a threat by Amicus to its next Fabry drug at
04:56AM  Sanofi confident dengue drug will benefit patients and investors at Financial Times
Jul-16-15 03:35PM  Sanofi Unveils Restructuring Plans, Prunes Business Units - Analyst Blog
01:45PM  Genzymes expansion is good news for Massachusetts, but comes with a price at
Jul-15-15 03:15PM  Cytokinetics Advances Tirasemtiv to Phase III, Shares Up - Analyst Blog
09:04AM  Sanofi trims number of divisions from seven to five
Jul-14-15 04:50PM  Anacor Hits 52-Week High on Positive Atopic Dermatitis Data - Analyst Blog
Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, including Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, as well as Toujeo, an insulin glargine. The company also offers Cerezyme to treat gaucher disease; Myozyme/Lumizyme for the pompe disease treatment; Fabrazyme for fabry disease treatment; and Aldurazyme to treat mucopolysaccharidosis type I, as well as provides Aubagio and Lemtrada for multiple sclerosis. In addition, it provides Jevtana for prostate cancer; Taxotere for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers; Thymoglobulin to treat acute rejection in organ transplantation, aplastic anemia, and graft-versus-host diseases; Eloxatin for colorectal cancer; Mozobil for treating hematologic malignancies; and Zaltrap for oxaliplatin resistant metastatic colorectal cancer. Further, the company offers other prescription drugs, such as Plavix for atherothrombosis and acute coronary syndrome; Lovenox for the treatment and prevention of deep vein thrombosis and acute coronary syndromes; Aprovel/CoAprovel for hypertension; Renagel/Renvela to treat chronic kidney disease; Depakine for epilepsy; Synvisc/Synvisc-One for the treatment of pain associated with osteoarthritis of the knee; Stilnox/Ambien/Myslee to treat sleep disorders; Multaq for atrial fibrillation; Allegra for the treatment of allergic rhinitis and urticarial; Actonel for osteoporosis and paget's disease; and Auvi-Q/Allerject for the treatment of severe allergic reactions. Additionally, it offers consumer health care products and generic medicines; and vaccine and animal health products. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanofi10% OwnerJul 27Buy537.4810,6395,718,27222,869,783Jul 29 05:46 PM
Sanofi10% OwnerDec 24Buy398.7930,00211,964,50122,859,144Dec 29 05:40 PM
Sanofi10% OwnerDec 23Buy392.23171,45767,251,14222,829,142Dec 29 05:40 PM
Sanofi10% OwnerOct 16Buy335.35122,12740,955,05722,657,685Oct 20 05:45 PM
Sanofi10% OwnerOct 15Buy328.16158,36851,970,26522,535,558Oct 17 05:05 PM